Proteovant Therapeutics
SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, is a U.S. biotech company focused on the discovery of transformative medicines through targeted protein degradation (TPD). We discover and develop therapies through precise degradation of disease-causing proteins. Our team takes a target-centric approach through AI enabled target identification. Our core TPD platform, built upon a strong TPD knowledge base, novel E3 ligands & linkers, and machine-learning based ternary complex modeling, is further complemented by a proprietary MOPED™ molecular glue platform. SK Life Science Labs integrates innovative platforms with deep drug-hunting expertise to defeat disease and improve patients’ lives. View our community guidelines here: http://bit.ly/3REsFKU
Proteovant Therapeutics
SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, is a U.S. biotech company focused on the discovery of transformative medicines through targeted protein degradation (TPD). We discover and develop therapies through precise degradation of disease-causing proteins. Our team takes a target-centric approach through AI enabled target identification. Our core TPD platform, built upon a strong TPD knowledge base, novel E3 ligands & linkers, and machine-learning based ternary complex modeling, is further complemented by a proprietary MOPED™ molecular glue platform. SK Life Science Labs integrates innovative platforms with deep drug-hunting expertise to defeat disease and improve patients’ lives. View our community guidelines here: http://bit.ly/3REsFKU
TL;DR
Focus: Targeted protein degradation therapeutics
Founded: 2021
Headcount (reported): 11–50
Known funding events: Seed round (Jan 2023); acquired by SK Group (announced Jun 30, 2023)
Company Overview
Problem Domain
Drug discovery for undruggable disease targets via targeted protein degradation.
Founded
2021
Industry
Biotechnology / Therapeutics
Funding Track Record
Seed round listed on Crunchbase
Acquisition of Proteovant announced
Investor Signal
“Plaisance Capital Management led seed; later acquired by SK Group”